Figure 2

Cognitive outcome and age. a) MMSE, prediction of outcome for different baseline scores and ages. Three-year mean outcomes with 95% confidence intervals predicted by the mixed models for patients with different Mini-Mental State Examination (MMSE) baseline scores (15, 20, and 25) and ages (65, 75, and 85 years), used as arbitrary examples. Older subjects with a baseline MMSE score < 22 exhibited a better six-month treatment response compared with younger patients (P < 0.001). In addition, the interaction MMSE score × Age at the start of ChEI treatment showed a more pronounced age difference at lower baseline scores (P < 0.001). The calculated outcomes were based on a male patient who did not receive NSAID/acetylsalicylic acid treatment, had nine years of education, exhibited an IADL baseline score of 16, and received 65% of the maximum recommended dose of ChEI. b) ADAS-cog, prediction of outcome for different baseline scores and ages. Three-year mean outcomes with 95% confidence intervals predicted by the models for patients with different Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) baseline scores (20, 30, and 40) and ages (65, 75, and 85 years), used as arbitrary examples. Older individuals exhibited a better response to treatment compared with younger subjects (P = 0.043). The interaction ADAS-cog score × Age at the start of treatment showed a greater age difference at lower baseline levels (P < 0.001). The calculated outcomes were based on a male patient who was an APOE ε4 carrier, did not receive NSAID/acetylsalicylic acid treatment, had nine years of education, exhibited an IADL baseline score of 16, and received 65% of the maximum recommended dose of ChEI.